PRESS

PRESS

ON-SITE CONFERENCE REPORTING BY GUEST AUTHOR KELLY KUNIK


Read the reports from the American Association of Diabetes Educators National Conference 2019 in
Houston, TX (August 9-12)
READ MORE

< Back to Press

2 November 2022

ASCENSIA LAUNCHES THE GLUCOCONTRO.ONLINE DIABETES MANAGEMENT AND ANALYTICS PLATFORM IN THE U.S.

Parsippany, United States

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has today launched its online diabetes management and analytics platform GlucoContro.online in the United States. Now available in more than 15 countries globally and in the process of further expansion, GlucoContro.online supports diabetes management by enabling data-driven care for people using the CONTOUR® BGM portfolio.

Through this single platform, people with diabetes (PWDs) can gather, access and analyze their diabetes data online and seamlessly share it with their healthcare providers (HCPs) and caregivers. The platform is intuitive and easy-to-use, and gathers data directly from the CONTOUR®DIABETES app, CONTOUR Cloud, or CONTOUR meters via a cable.

To support PWDs and HCPs in their decision-making, GlucoContro.online has built-in data analytic capabilities. It provides users with color-coded charts and reports covering metrics such as blood glucose measurements, insulin dosing, food consumption and activity levels. This data can be shared seamlessly through a QR code or a simple one-click invitation and is held securely on the cloud as well as offline.

GlucoContro.online will be launched alongside CONTOUR®NEXT Concierge, Ascensia’s HCP-focused online platform for ordering CONTOUR meters and strips. With one login and within one uninterrupted system, HCPs will be able to rapidly access patient data as well as order essential supplies and samples from the CONTOUR® portfolio.

Chester Lu, Head BGM Digital Connected Solutions, said: “GlucoContro.online gives PWDs and HCPs access to essential data wherever they are, providing them with peace of mind when making decisions both on a daily basis and for long-term treatment plans. The platform is already fully operational across Europe, and we are glad that people in the U.S. are now able to benefit from this intuitive and integrated approach to data-driven diabetes management. GlucoContro.online is just one of the ways in which Ascensia is supporting PWDs and HCPs to simplify life with diabetes.”

GlucoContro.online is the outcome of a collaboration between Ascensia and SdNcenter, a Poland-based company specialized in delivering high-tech healthcare and integration solutions for enterprise customers worldwide. This cooperation has resulted in a scalable platform which is capable of handling data from over 150 million patients, 10,000 clinics and 100,000 HCPs. It has also been designed to be able to collect additional data from other devices in the future, such as FitBit, Apple Health, Google Health and Smart Scales.

PWDs and HCPs interested in learning more about GlucoContro.online can head to https://glucocontro.online  


Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries. For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

About SdNcenter

SdNcenter is the legal manufacturer and developer of GlucoContro.online and is partnering with Ascensia to market and deliver the tool to HCP and Patient users.

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries. www.phchd.com

©2022 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

For media enquiries, please contact:

Tim Stamper, Tim.Stamper@FTIConsulting.com